Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ACP3 | P15309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18300626 | 0.85 | ESR1 (0.44) | KMT2AESR1PTGS1PTGS2ALDH1A1 | |
| SCHEMBL6240135 | 0.84 | KMT2A (0.47) | KMT2APTGS1PTGS2ALDH1A1MEN1 | |
| SCHEMBL7625256 | 0.83 | KMT2A (0.43) | KMT2AESR1ALDH1A1MEN1PLA2G1B | |
| SCHEMBL1345444 | 0.82 | GABRA1 (0.52) | KMT2APTGS1PTGS2ALDH1A1MEN1 | |
| SCHEMBL363983 | 0.82 | TSHR (0.48) | KMT2AESR1ALDH1A1MEN1GLS | |
| SCHEMBL9666407 | 0.82 | KMT2A (0.46) | KMT2AESR1ALDH1A1MEN1PLA2G1B | |
| SCHEMBL7056831 | 0.82 | ESR1 (0.45) | ESR1ALDH1A1GLSKDM4EMAPK1 | |
| SCHEMBL31517035 | 0.82 | GABRA1 (0.52) | KMT2APTGS1PTGS2ALDH1A1MEN1 | |
| SCHEMBL5541713 | 0.82 | LPAR1 (0.49) | KMT2APTGS1PTGS2ALDH1A1HTT | |
| SCHEMBL9666399 | 0.82 | KMT2A (0.46) | KMT2AESR1ALDH1A1MEN1PLA2G1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195434-B2 | Process for the preparation of a chiral prostaglandin enol intermediate and intermediate compounds useful in the process | EUROAPI HUNGARY LIMITED LIABILITY COMPANY (HU) | 2025-01-14 | — | — | US | disclosed |
| US-20230111101-A1 | PROCESS FOR THE PREPARATION OF A CHIRAL PROSTAGLANDIN ENOL INTERMEDIATE AND INTERMEDIATE COMPOUNDS USEFUL IN THE PROCESS | EUROAPI HUNGARY LIMITED LIABILITY COMPANY (HU) | 2023-04-13 | — | — | US | disclosed |
| EP-4077298-A1 | PROCESS FOR THE PREPARATION OF A CHIRAL PROSTAGLANDIN ENOL INTERMEDIATE AND INTERMEDIATE COMPOUNDS USEFUL IN THE PROCESS | EUROAPI Hungary Limited Liability Company (HU) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021123848-A1 | PROCESS FOR THE PREPARATION OF A CHIRAL PROSTAGLANDIN ENOL INTERMEDIATE AND INTERMEDIATE COMPOUNDS USEFUL IN THE PROCESS | CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. (HU) | 2021-06-24 | — | — | WO | disclosed |
| CN-101641342-B | Thiazolidine derivatives as orexin receptor antagonist | ACTELION PHARMACEUTICAL LTD CH | 2012-10-03 | — | — | CN | disclosed |
| CN-101641342-A | Thiazolidine derivatives | ACTELION PHARMACEUTICAL LTD CH | 2010-02-03 | — | — | CN | disclosed |
| EP-1684694-A2 | AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005051304-A2 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230111101-A1 | PROCESS FOR THE PREPARATION OF A CHIRAL PROSTAGLANDIN ENOL INTERMEDIATE AND INTERMEDIATE COMPOUNDS USEFUL IN THE PROCESS | PTGER1, PTGER4, PTGER2 | KMT2A 4860/4885ESR1 2246/4885PTGS1 9/4885 |
| US-12195434-B2 | Process for the preparation of a chiral prostaglandin enol intermediate and intermediate compounds useful in the process | PTGER1, PTGER4, PTGER2 | KMT2A 4860/4885ESR1 2246/4885PTGS1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.